SRR5088823
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.600
- BILE_ACID_METABOLISM+0.500
- FATTY_ACID_METABOLISM+0.400
- PEROXISOME+0.400
- ADIPOGENESIS+0.300
- ALLOGRAFT_REJECTION+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- ESTROGEN_RESPONSE_LATE+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- E2F_TARGETS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- G2M_CHECKPOINT-0.300
- NOTCH_SIGNALING-0.300
- PROTEIN_SECRETION-0.300
- DNA_REPAIR-0.200
- MITOTIC_SPINDLE-0.200
- MYC_TARGETS_V1-0.200
- UV_RESPONSE_DN-0.200
- ANGIOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0960_T2_RNA | — | C | 0.813 |
| 2 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.790 |
| 3 | MBCProject_0217_T2_RNA | — | C | 0.780 |
| 4 | TCGA-75-7031-01A-11R-1949-07 | — | cohortA3 | 0.753 |
| 5 | TCGA-E2-A1IK-01A-11R-A144-07 | — | B | 0.717 |
| 6 | TCGA-OR-A5LH-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.705 |
| 7 | SRR975601 | — | — | 0.705 |
| 8 | ERR2208921 | — | — | 0.704 |
| 9 | SRR975594 | — | — | 0.701 |
| 10 | SRR15030868 | — | — | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.600 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.500 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |